VANGUARD GROUP INC - CTI BIOPHARMA CORP ownership

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q4 2016$3,060,000
+11.0%
7,591,552
+3.1%
0.00%
Q3 2016$2,756,000
+6.1%
7,362,722
-3.6%
0.00%
Q2 2016$2,598,000
-41.3%
7,638,471
-8.3%
0.00%
Q1 2016$4,425,000
-45.8%
8,327,849
+25.4%
0.00%
-100.0%
Q4 2015$8,167,000
-96.8%
6,639,241
-64.1%
0.00%
-88.9%
Q3 2015$252,496,000
+2209.5%
18,502,626
+230.0%
0.01%
+800.0%
Q2 2015$10,933,000
+12.5%
5,606,669
+4.4%
0.00%0.0%
Q1 2015$9,722,000
-10.3%
5,370,846
+16.9%
0.00%0.0%
Q4 2014$10,839,000
+7.5%
4,592,711
+10.2%
0.00%0.0%
Q3 2014$10,085,000
-6.6%
4,167,379
+8.4%
0.00%0.0%
Q2 2014$10,803,0003,844,5790.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q1 2017
NameSharesValueWeighting ↓
EAGLE ASSET MANAGEMENT INC 15,707,022$38,010,0000.11%
First Heartland Consultants, Inc. 74,624$181,0000.08%
WASHINGTON TRUST Co 410,616$994,0000.07%
Geduld E E 40,000$97,0000.07%
FIRST NEW YORK SECURITIES LLC /NY 30,562$73,960,0000.05%
Crosspoint Capital Strategies, LLC 25,000$61,0000.04%
JANE STREET GROUP, LLC 1,434,975$3,473,0000.04%
MAGEE THOMSON INVESTMENT PARTNERS LLC 21,479$51,0000.01%
TIAA CREF TRUST CO FSB/MO 296,322$717,0000.01%
Investors Capital Advisory Services 16,950$41,0000.01%
View complete list of CTI BIOPHARMA CORP shareholders